Abstract
Newer CML kinase inhibitors increase ischemia risk and are toxic to endothelial cells where they produce a proteomic toxicity signature.
This phosphoproteomic EC toxicity signature predicts bosutinib to be safe, providing a potential screening tool for safer drug development.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Aniline Compounds / adverse effects*
-
Aniline Compounds / pharmacology
-
Human Umbilical Vein Endothelial Cells / metabolism*
-
Human Umbilical Vein Endothelial Cells / pathology
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Nitriles / adverse effects*
-
Nitriles / pharmacology
-
Phosphoproteins / metabolism*
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / pharmacology
-
Proteomics*
-
Quinolines / adverse effects*
-
Quinolines / pharmacology
Substances
-
Aniline Compounds
-
Nitriles
-
Phosphoproteins
-
Protein Kinase Inhibitors
-
Quinolines
-
bosutinib